Oncopeptides
ISIN: SE0009414576 | Ticker: ONCO | LEI: 549300J9WWQ5CBYQ1M77
Country: Sweden
Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and is committed to bringing innovation to patients with an unmet need and improving patient quality of life.
Oncopeptides uses its proprietary Peptide Drug Candidate platform, PDC, to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.
The headquarters is in Stockholm, Sweden, and a modern pre-clinical drug development facility in Solna, outside Stockholm, Sweden.
2000
Served areaWorldwide
HeadquartersLuntmakargatan 46, 7th floor, 11137 Stockholm – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 946,756,000.00 | 439,376,000.00 | 385,323,000.00 |
| Noncurrent Assets | N/A | 51,957,000.00 | 27,003,000.00 | 21,289,000.00 |
| Property Plant And Equipment | N/A | 17,273,000.00 | 10,348,000.00 | 10,501,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 1,830,000.00 | 1,408,000.00 | 0.00 |
| Deferred Tax Assets | N/A | 8,175,000.00 | 0.00 | 0.00 |
| Current Assets | N/A | 894,799,000.00 | 412,373,000.00 | 364,034,000.00 |
| Inventories | N/A | 8,665,000.00 | 0.00 | 0.00 |
| Current Trade Receivables | N/A | 0.00 | 11,873,000.00 | 674,000.00 |
| Current Prepaid Expenses | N/A | 22,650,000.00 | 12,189,000.00 | 2,251,000.00 |
| Other Current Receivables | N/A | 23,229,000.00 | 26,125,000.00 | 16,594,000.00 |
| Cash and cash equivalents | 926,186,000.00 | 840,255,000.00 | 362,187,000.00 | 344,515,000.00 |
| Equity And Liabilities | N/A | 946,756,000.00 | 439,376,000.00 | 385,323,000.00 |
| Equity | 797,013,000.00 | 576,897,000.00 | 210,868,000.00 | 294,293,000.00 |
| Issued Capital | N/A | 7,549,000.00 | 8,366,000.00 | 10,479,000.00 |
| Retained Earnings | N/A | -3,348,146,000.00 | -4,778,463,000.00 | -5,116,414,000.00 |
| Other Reserves | N/A | -1,542,000.00 | -918,000.00 | -2,297,000.00 |
| Additional Paidin Capital | N/A | 3,919,036,000.00 | 4,981,883,000.00 | 5,402,525,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 576,897,000.00 | 210,868,000.00 | 294,293,000.00 |
| Liabilities | N/A | 369,859,000.00 | 228,508,000.00 | 91,030,000.00 |
| Noncurrent Liabilities | N/A | 15,459,000.00 | 3,219,000.00 | 5,358,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 8,530,000.00 | 13,000.00 | 1,815,000.00 |
| Current Liabilities | N/A | 354,400,000.00 | 225,289,000.00 | 85,672,000.00 |
| Current Provisions For Employee Benefits | N/A | 47,202,000.00 | 45,000.00 | 2,494,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 136,135,000.00 | 35,702,000.00 | 28,219,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 121,611,000.00 | 18,788,000.00 |
| Other Current Payables | N/A | 35,045,000.00 | 67,931,000.00 | 36,171,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue From Contracts With Customers | 0.00 | 118,295,000.00 | 8,355,000.00 |
| Other Income | 0.00 | 71,536,000.00 | 6,035,000.00 |
| Profit Loss From Operating Activities | -1,591,279,000.00 | -1,420,917,000.00 | -349,350,000.00 |
| Finance Income | 322,000.00 | 492,000.00 | 12,553,000.00 |
| Finance Costs | 1,485,000.00 | 948,000.00 | 883,000.00 |
| Profit Loss Before Tax | -1,592,442,000.00 | -1,421,372,000.00 | -337,680,000.00 |
| Income Tax Expense Continuing Operations | 2,251,000.00 | 8,946,000.00 | 271,000.00 |
| Profit (loss) | -1,594,693,000.00 | -1,430,317,000.00 | -337,951,000.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -1,594,693,000.00 | -1,430,317,000.00 | -337,951,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -429,000.00 | -319,000.00 | 0.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | 55,149,000.00 | -104,911,000.00 | -22,887,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 1,485,000.00 | 948,000.00 | 883,000.00 |
| Interest Received Classified As Operating Activities | N/A | 322,000.00 | 96,000.00 | 2,616,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -1,296,509,000.00 | -1,516,391,000.00 | -420,509,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 17,180,000.00 | 339,000.00 | 2,507,000.00 |
| Purchase Of Other Longterm Assets Classified As Investing Activities | N/A | 3,131,000.00 | 0.00 | 0.00 |
| Cash Flows From Used In Investing Activities | N/A | -20,127,000.00 | -339,000.00 | -2,507,000.00 |
| Proceeds From Issuing Shares | N/A | 1,413,925,000.00 | 1,106,000,000.00 | 436,015,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 14,260,000.00 | 15,405,000.00 | 15,542,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 1,323,461,000.00 | 1,034,030,000.00 | 392,402,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 6,825,000.00 | -482,700,000.00 | -30,614,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -92,756,000.00 | 4,633,000.00 | 12,942,000.00 |
| Cash and cash equivalents | 926,186,000.00 | 840,255,000.00 | 362,187,000.00 | 344,515,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 08.09.23 | David Augustsson | Other | Buy | SEK 17,706.75 |
| 10.08.23 | David Augustsson | Other | Buy | SEK 14,995.20 |
| 04.05.23 | Nicolaas Bakker | Other | Buy | SEK 42,380.00 |
| 10.10.22 | Nicolaas Bakker | Other | Buy | SEK 164,400.00 |
| 30.08.22 | Per Wold-Olsen | Other | Buy | SEK 55,350.00 |
| 30.08.22 | Per Wold-Olsen | Other | Buy | SEK 53,840.00 |
| 30.08.22 | Per Wold-Olsen | Other | Buy | SEK 45,851.88 |
| 30.08.22 | Per Wold-Olsen | Other | Buy | SEK 45,730.00 |
| 30.08.22 | Per Wold-Olsen | Other | Buy | SEK 32,612.23 |
| 30.08.22 | Per Wold-Olsen | Other | Buy | SEK 27,669.81 |
SE0009414576
LEI549300J9WWQ5CBYQ1M77
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.